PROTECTIVE EFFECTS OF PROPIONYL-L-CARNITINE DURING ISCHEMIA AND REPERFUSION

被引:32
|
作者
SHUG, A
PAULSON, D
SUBRAMANIAN, R
REGITZ, V
机构
[1] UNIV WISCONSIN,SCH MED,MADISON,WI 53706
[2] SCH OSTEOPATH MED,CHICAGO,IL
[3] HERZZENTRUM,BERLIN,GERMANY
关键词
PROPIONYL-L-CARNITINE; ISCHEMIA; REPERFUSION FATTY ACIDS; FREE RADICALS;
D O I
10.1007/BF00128246
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
When cardiac function in isolated rat hearts was impaired by subject them to ischemia, subsequent perfusion with propionyl-L-carnitine and related compounds increased their rate of recovery. Thus at 11 mM, both propionyl-L-carnitine and, to a lesser extent, its taurine amide, and also acetyl-L-carnitine, significantly restored cardiac function in 15 minutes after 90 minutes of either low-flow or intermittent no-flow ischemia. Carnitine itself was ineffective. Propionyl-L-carnitine also increased tissue ATP and creatine phosphate compared with controls, but did not affect the levels of long-chain acyl carnitine and coenzyme. These esters also depleted fatty acid peroxidation, as shown with malonaldehyde, and were more effective than carnitine in preventing the production of superoxide. In myocytes, propionyl-L-carnitine alone stimulated palmitate oxidation, but in rat heart homogenates, both L-carnitine and propionyl-L-carnitine did so, while acetyl-L-carnitine was actually inhibitory. Possible mechanisms for the protective action of propionyl-L-carnitine against ischemia include an increased rate of cellular transport, stimulation of fatty acid oxidation, and a reduction of free radical formation.
引用
收藏
页码:77 / 84
页数:8
相关论文
共 50 条
  • [31] European multicenter study on propionyl-L-carnitine in intermittent claudication
    Brevetti, G
    Diehm, C
    Lambert, D
    CIRCULATION, 1997, 96 (08) : 710 - 710
  • [32] Effects of propionyl-L-carnitine topical irrigation in distal ulcerative colitis: A preliminary report
    Gasbarrini, G
    Mingrone, G
    Giancaterini, A
    De Gaetano, A
    Scarfone, A
    Capristo, E
    Calvani, M
    Caso, V
    Greco, AV
    HEPATO-GASTROENTEROLOGY, 2003, 50 (53) : 1385 - 1389
  • [33] PROLONGED PROPIONYL-L-CARNITINE PRETREATMENT OF RABBIT - BIOCHEMICAL, HEMODYNAMIC AND ELECTROPHYSIOLOGICAL EFFECTS ON MYOCARDIUM
    FERRARI, R
    DILISA, F
    DEJONG, JW
    CECONI, C
    PASINI, E
    BARBATO, R
    MENABO, R
    BARBIERI, M
    CERBAI, E
    MUGELLI, A
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 1992, 24 (03) : 219 - 232
  • [34] The Effects of L-Carnitine, Acetyl-L-Carnitine, and Propionyl-L-Carnitine on Body Mass in Type 2 Diabetes Mellitus Patients
    Wang, Dong-Dong
    Wang, Tian-Yun
    Yang, Yang
    He, Su-Mei
    Wang, You-Mei
    FRONTIERS IN NUTRITION, 2021, 8
  • [35] Effects of propionyl-L-carnitine on isolated mitochondrial function in the reperfused diabetic rat heart
    Felix, C
    Gillis, M
    Driedzic, WR
    Paulson, DJ
    Broderick, TL
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2001, 53 (01) : 17 - 24
  • [36] MEMBRANE STABILIZING EFFECTS OF PROPIONYL-L-CARNITINE - IN-VIVO AND IN-VITRO EVIDENCES
    DEBERNARDIS, E
    CARUSO, A
    CUTULI, VMC
    LEONARDI, G
    AMICOROXAS, M
    ALBERGHINA, M
    AGENTS AND ACTIONS, 1994, 41 : C219 - C220
  • [37] Propionyl-l-carnitine prevents the development of neointima in an experimental model of restenosis
    Orlandi, A
    Marcellini, M
    Spagnoli, LG
    ATHEROSCLEROSIS, 1997, 134 (1-2) : 267 - 267
  • [38] EFFECT OF PROPIONYL-L-CARNITINE ON MECHANICAL FUNCTION OF ISOLATED RABBIT HEART
    FERRARI, R
    PASINI, E
    CONDORELLI, E
    BORASO, A
    LISCIANI, R
    MARZO, A
    VISIOU, O
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 : 17 - 24
  • [39] FUNCTIONAL AND METABOLIC EFFECTS OF PROPIONYL-L-CARNITINE IN THE ISOLATED PERFUSED HYPERTROPHIED RAT-HEART
    MOTTERLINI, R
    SAMAJA, M
    TARANTOLA, M
    MICHELETTI, R
    BIANCHI, G
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 1992, 116 (1-2) : 139 - 145
  • [40] PROPIONYL-L-CARNITINE - BIOCHEMICAL SIGNIFICANCE AND POSSIBLE ROLE IN CARDIAC METABOLISM
    SILIPRANDI, N
    DILISA, F
    MENABO, R
    CARDIOVASCULAR DRUGS AND THERAPY, 1991, 5 : 11 - 16